Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Longitudinal stability of CSF biomarkers in Alzheimer's disease

Blennow, Kaj ; Zetterberg, Henrik ; Minthon, Lennart LU ; Lannfelt, Lars ; Strid, Stig ; Annas, Peter ; Basun, Hans and Andreasen, Niels (2007) In Neuroscience Letters 419(1). p.18-22
Abstract
Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181)) and the 42 amino acid isoform of beta-amyloid (A beta 42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (+/- S.D.) 76.1 +/- 7.9 years. Mean levels of CSF biomarkers were very stable between... (More)
Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181)) and the 42 amino acid isoform of beta-amyloid (A beta 42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (+/- S.D.) 76.1 +/- 7.9 years. Mean levels of CSF biomarkers were very stable between baseline and endpoint, with coefficients of variation (CVs) of 4.4-6.1%. Intra-individual biomarker levels at baseline and endpoint were also highly correlated with Pearson r-values above 0.95 (p < 0.0001), for all three markers. We conclude that T-tau, P-tau and A beta 42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients. This suggest that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness as surrogate markers in clinical trials with drug candidates with disease-modifying potential, such as secretase inhibitors, A beta immunotherapy and tau phosphorylation inhibitors. (c) 2007 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
clinical trials, cerebrospinal fluid (CSF), biomarkers, beta-amyloid, tau protein, longitudinal
in
Neuroscience Letters
volume
419
issue
1
pages
18 - 22
publisher
Elsevier
external identifiers
  • wos:000246815200005
  • scopus:34247893817
  • pmid:17482358
ISSN
0304-3940
DOI
10.1016/j.neulet.2007.03.064
language
English
LU publication?
yes
id
6a2db2e6-83c8-41a9-8f0c-82a25cbb41cd (old id 657427)
date added to LUP
2016-04-01 12:34:24
date last changed
2025-04-04 14:48:28
@article{6a2db2e6-83c8-41a9-8f0c-82a25cbb41cd,
  abstract     = {{Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau(181)) and the 42 amino acid isoform of beta-amyloid (A beta 42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (+/- S.D.) 76.1 +/- 7.9 years. Mean levels of CSF biomarkers were very stable between baseline and endpoint, with coefficients of variation (CVs) of 4.4-6.1%. Intra-individual biomarker levels at baseline and endpoint were also highly correlated with Pearson r-values above 0.95 (p &lt; 0.0001), for all three markers. We conclude that T-tau, P-tau and A beta 42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients. This suggest that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness as surrogate markers in clinical trials with drug candidates with disease-modifying potential, such as secretase inhibitors, A beta immunotherapy and tau phosphorylation inhibitors. (c) 2007 Elsevier Ireland Ltd. All rights reserved.}},
  author       = {{Blennow, Kaj and Zetterberg, Henrik and Minthon, Lennart and Lannfelt, Lars and Strid, Stig and Annas, Peter and Basun, Hans and Andreasen, Niels}},
  issn         = {{0304-3940}},
  keywords     = {{clinical trials; cerebrospinal fluid (CSF); biomarkers; beta-amyloid; tau protein; longitudinal}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{18--22}},
  publisher    = {{Elsevier}},
  series       = {{Neuroscience Letters}},
  title        = {{Longitudinal stability of CSF biomarkers in Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1016/j.neulet.2007.03.064}},
  doi          = {{10.1016/j.neulet.2007.03.064}},
  volume       = {{419}},
  year         = {{2007}},
}